Skip to main content Accessibility help
×
Home

Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia

  • Camilla L. Wong (a1), Nick Bansback (a2), Philip E. Lee (a3) and Aslam H. Anis (a2) (a4)

Abstract

Background:

Several randomized controlled trials of cholinesterase inhibitors and memantine in mild to moderate vascular dementia have demonstrated the efficacy of these treatments. However, given these drugs incur considerable cost, the economic argument for their use is less clear.

Objective:

To determine the incremental cost-effectiveness of cholinesterase inhibitors and memantine for mild to moderate vascular dementia.

Design:

A decision analysis model using a 24-28 week time horizon was developed. Outcomes of cholinesterase inhibitors and memantine and probabilities of adverse events were extracted from a systematic review. Costs of adverse events, medications, and physician visits were obtained from local estimates. Robustness was tested with probabilistic sensitivity analysis using a Monte Carlo simulation.

Interventions:

Donepezil 5 mg daily, donepezil 10 mg daily, galantamine 16-24 mg daily, rivastigmine flexible dosing up to 6 mg twice daily, or memantine 10 mg twice daily versus standard care.

Main Outcome Measures:

Incremental cost-effectiveness ratio (ICER) expressed as cost per unit decrease in the Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) subscale.

Results:

Donepezil 10 mg daily was found to be the most cost-effective treatment with an ICER of $400.64 (95%CI, $281.10-$596.35) per unit decline in the ADAS-cog subscale. All other treatments were dominated by donepezil 10 mg, that is, more costly and less effective.

Conclusion:

From a societal perspective, treatment with cholinesterase inhibitors or memantine was more effective but also more costly than standard care for mild to moderate vascular dementia. The donepezil 10 mg strategy was the most cost-effective and also dominated the other alternatives.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia
      Available formats
      ×

Copyright

Corresponding author

Division of Geriatric Medicine, St. Michael’s Hospital, 30 Bond Street, Office 4-002, Toronto, Ontario, Canada, M5B 1W8.

References

Hide All
1.Ostbye, T, Crosse, E.Net economic costs of dementia in Canada. CMAJ. 1994;151:145764.
2.Health Canada. Economic burden of illness in Canada, 1998. Catalogue number: H21-136/1998E; 2002.
3.Rockwood, K, Wentzel, C, Hachinski, V, Hogan, DB, MacKnight, C, McDowell, I.Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54: 44751.
4.Feldman, H, Levy, AR, Hsiung, GY, Peters, KR, Donald, A, Black, SEet al.A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003;22:26574.
5.Swartz, RH, Sahlas, DJ, Black, SE.Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis. 2003;12:2936.
6.Auchus, AP, Brashear, HR, Salloway, S, Korczyn, AD, De Deyn, PP, Gassmann-Mayer, C, et al.Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007;69:44858.
7.Black, S, Roman, GC, Geldmacher, DS, Salloway, S, Hecker, J, Burns, A, et al.Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:232330.
8.Erkinjuntti, T, Kurz, A, Gauthier, S, Bullock, R, Lilienfeld, S, Damaraju, CV.Efficacy of galantamine in probable vascular dementia and Alzheimer’s’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359: 128390.
9.Wilkinson, D, Doody, R, Helme, R, Taubman, K, Mintzer, J, Kertesz, A, et al.Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:47986.
10.Lancelot, E, Beal, MF.Glutamate toxicity in chronic neuro-degenerative disease. Prog Brain Res. 1998;116:33147.
11.Mobius, HJ.Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord. 1999;13 Suppl 3:S1728.
12.Orgogozo, JM, Rigaud, AS, Stoffler, A, Mobius, HJ, Forette, F.Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:18349.
13.Wilcock, G, Mobius, HJ, Stoffler, A; MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297305.
14.Kavirajan, H, Schneider, LS.Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:78292.
15.Bocti, C, Black, S, Frank, C.Management of dementia with a cerebrovascular component. Alzheimers Dement. 2007;3: 398403.
16.Roman, GC, Tatemichi, TK, Erkinjuntti, T, Cummings, JL, Masdeu, JC, Garcia, JH, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:25060.
17.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-III-R. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
18.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19.Briggs, AH.Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479500.
20.Korczyn, AD.Drugs for vascular dementia. Lancet Neurology. 2007;6:74951.

Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia

  • Camilla L. Wong (a1), Nick Bansback (a2), Philip E. Lee (a3) and Aslam H. Anis (a2) (a4)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed